

**VIPR1 Antibody (Cytoplasmic Domain)**  
**Rabbit Polyclonal Antibody**  
**Catalog # ALS10325****Specification****VIPR1 Antibody (Cytoplasmic Domain) - Product Information**

Application	IHC
Primary Accession	<a href="#">P32241</a>
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Calculated MW	52kDa KDa

**VIPR1 Antibody (Cytoplasmic Domain) - Additional Information****Gene ID** 7433**Other Names**

Vasoactive intestinal polypeptide receptor 1, VIP-R-1, Pituitary adenylate cyclase-activating polypeptide type II receptor, PACAP type II receptor, PACAP-R-2, PACAP-R2, VPAC1, VIPR1

**Target/Specificity**

Human VIP Receptor 1. BLAST analysis of the peptide immunogen showed no homology with other human proteins, except GHRHR (56%).

**Reconstitution & Storage**

Long term: -70°C; Short term: +4°C

**Precautions**

VIPR1 Antibody (Cytoplasmic Domain) is for research use only and not for use in diagnostic or therapeutic procedures.

**VIPR1 Antibody (Cytoplasmic Domain) - Protein Information****Name** VIPR1 ([HGNC:12694](#))**Function**

G protein-coupled receptor activated by the neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (ADCYAP1/PACAP) (PubMed: [35477937](http://www.uniprot.org/citations/35477937), PubMed: [36385145](http://www.uniprot.org/citations/36385145), PubMed: [8179610](http://www.uniprot.org/citations/8179610)). Binds VIP and both PACAP27 and PACAP38 bioactive peptides with the following order of ligand affinity VIP = PACAP27 > PACAP38 (PubMed: [35477937](http://www.uniprot.org/citations/35477937), PubMed: [8179610](http://www.uniprot.org/citations/8179610)). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors. Activates cAMP-dependent pathway (PubMed: [35477937](#))

href="http://www.uniprot.org/citations/35477937" target="\_blank">35477937</a>, PubMed:<a href="http://www.uniprot.org/citations/36385145" target="\_blank">36385145</a>, PubMed:<a href="http://www.uniprot.org/citations/8179610" target="\_blank">8179610</a>).

#### Cellular Location

Cell membrane; Multi-pass membrane protein

#### Tissue Location

In lung, HT-29 colonic epithelial cells, Raji B- lymphoblasts. Lesser extent in brain, heart, kidney, liver and placenta. Not expressed in CD4+ or CD8+ T-cells. Expressed in the T- cell lines HARRIS, HuT 78, Jurkat and SUP-T1, but not in the T-cell lines Peer, MOLT-4, HSB and YT.

#### Volume


50 µl

### VIPR1 Antibody (Cytoplasmic Domain) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


### VIPR1 Antibody (Cytoplasmic Domain) - Images



Anti-VIPR1 / RDC1 antibody IHC of human Pancreas, Carcinoma.



Anti-VIPR1 / RDC1 antibody IHC of human Lung, Adenocarcinoma.



Anti-VIPR1 / RDC1 antibody IHC of human Breast, Carcinoma.

### **VIPR1 Antibody (Cytoplasmic Domain) - Background**

This is a receptor for VIP. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The affinity is VIP = PACAP-27 > PACAP-38.

### **VIPR1 Antibody (Cytoplasmic Domain) - References**

Sreedharan S.P., et al. *Biochem. Biophys. Res. Commun.* 193:546-553(1993).  
Couvineau A., et al. *Biochem. Biophys. Res. Commun.* 200:769-776(1994).  
Suwa M., et al. Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.  
Martin A.L., et al. Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases.  
Ota T., et al. *Nat. Genet.* 36:40-45(2004).